The facts investigated and proved, as stated above, showed that low-dose IL2 shows promise as a treatment modality for SLE patients; however, it was seen in this study that the immunomodulation induced by low-dose IL2 was transient [18]. This evidence concerns the gene IL2 and systemic lupus erythematosus.